|
|
precipitation and citrate
Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders.
The Tokai journal of experimental and clinical medicine
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.
Current hematologic malignancy reports
JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera.
Leukemia & lymphoma
[Tyrosine kinase JAK2V617F mutation in human myeloproliferative disorders].
Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology
Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational load in myeloid lineages and rare involvement of lymphoid cells.
The American journal of surgical pathology
Absence of JAK2 V617F mutation in thalassemia intermedia patients.
Molecular biology reports
Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation.
International journal of hematology
Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
The American journal of surgical pathology
The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.
Blood
The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age.
Best practice & research. Clinical haematology
[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Orvosi hetilap
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
Lancet
[Abnormal activation of tyrosine kinases and its role in the pathogenesis of hematological malignancies - review].
Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
Blood
The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Seminars in thrombosis and hemostasis
Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
The Journal of molecular diagnostics : JMD
Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis.
Archives of pathology & laboratory medicine
[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].
Medizinische Klinik (Munich, Germany : 1983)
A role for JAK2 mutations in myeloproliferative diseases.
Annual review of medicine
Advances in the therapy of chronic idiopathic myelofibrosis.
The oncologist
The Tokai journal of experimental and clinical medicine
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.
Current hematologic malignancy reports
JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera.
Leukemia & lymphoma
[Tyrosine kinase JAK2V617F mutation in human myeloproliferative disorders].
Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology
Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational load in myeloid lineages and rare involvement of lymphoid cells.
The American journal of surgical pathology
Absence of JAK2 V617F mutation in thalassemia intermedia patients.
Molecular biology reports
Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation.
International journal of hematology
Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
The American journal of surgical pathology
The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.
Blood
The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age.
Best practice & research. Clinical haematology
[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Orvosi hetilap
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
Lancet
[Abnormal activation of tyrosine kinases and its role in the pathogenesis of hematological malignancies - review].
Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
Blood
The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Seminars in thrombosis and hemostasis
Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
The Journal of molecular diagnostics : JMD
Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis.
Archives of pathology & laboratory medicine
[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].
Medizinische Klinik (Munich, Germany : 1983)
A role for JAK2 mutations in myeloproliferative diseases.
Annual review of medicine
Advances in the therapy of chronic idiopathic myelofibrosis.
The oncologist
Get breaking news about nutritional cures, dangerous chemicals, superfoods and more.
Subscribe to the FREE Natural News email newsletter. Your privacy is protected.
See more studies on precipitation and...
How is this determined?
The order of these related concepts is determined by a statistical analysis of the scientific literature. Highest-frequency concepts appear first.
|
water 1250 Calcium 683 Sulfate 473 sodium 446 soil 373 salt 296 ethanol 288 Polyethylene 288 Polyethylene glycol 248 Chloride 243 blood 230 Cholesterol 223 summer 220 nitrogen 207 lead 204 Iron 187 ammonium sulfate 187 climate change 178 winter 175 Magnesium 169 Phosphorus 162 hydrogen 148 weather 127 environment 127 calcium carbonate 116 Nitrate 114 |
Cellulose 114 tropical 112 Zinc 109 agar 105 copper 101 Enzymes 100 drought 100 CO2 95 HDL 90 Silica 81 emissions 76 Alcohol 74 grassland 69 Aluminum 65 soil moisture 64 Glucose 60 lakes 53 citrate 49 Mercury 48 Lysozyme 45 Phospholipids 39 Insulin 37 chitosan 26 oak 22 Caprylic acid 21 |
